Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Stock Information for Alector Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Alector Inc.

Alector Provides Executive Leadership Update
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
Alector to Participate in Upcoming Healthcare Conferences
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease
Alector Provides Executive Leadership Update
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Alector to Participate in Upcoming Healthcare Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.